News coverage about Alder BioPharmaceuticals (NASDAQ:ALDR) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alder BioPharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.5224356327869 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Analytical Review of Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) – The Oracle Examiner (oracleexaminer.com)
- Zacks: Analysts Expect Alder BioPharmaceuticals, Inc. (ALDR) Will Post Earnings of -$1.10 Per Share (americanbankingnews.com)
- Leerink Swann Weighs in on Alder BioPharmaceuticals, Inc.’s FY2017 Earnings (ALDR) (americanbankingnews.com)
- Alder BioPharmaceuticals, Inc. (ALDR) Forecasted to Earn Q1 2018 Earnings of ($1.00) Per Share (americanbankingnews.com)
- Mizuho Reaffirms “Buy” Rating for Alder BioPharmaceuticals, Inc. (ALDR) (americanbankingnews.com)
A number of brokerages have weighed in on ALDR. ValuEngine raised shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, September 30th. Mizuho restated a “buy” rating and issued a $32.00 price objective on shares of Alder BioPharmaceuticals in a research note on Wednesday, November 8th. Cowen and Company initiated coverage on shares of Alder BioPharmaceuticals in a research note on Tuesday, September 26th. They issued an “outperform” rating and a $20.00 price objective for the company. Canaccord Genuity initiated coverage on shares of Alder BioPharmaceuticals in a research note on Thursday, October 26th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Royal Bank Of Canada initiated coverage on shares of Alder BioPharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $17.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the stock. Alder BioPharmaceuticals currently has an average rating of “Buy” and a consensus target price of $28.07.
Alder BioPharmaceuticals (ALDR) opened at $9.95 on Wednesday. Alder BioPharmaceuticals has a one year low of $8.60 and a one year high of $34.30.
Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($1.21) by $0.29. During the same quarter in the prior year, the business posted ($0.70) EPS. research analysts expect that Alder BioPharmaceuticals will post -5.36 earnings per share for the current fiscal year.
In other Alder BioPharmaceuticals news, insider Mark James Litton sold 16,520 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $12.33, for a total value of $203,691.60. Following the transaction, the insider now owns 116,452 shares of the company’s stock, valued at $1,435,853.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 10.60% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://weekherald.com/2017/11/15/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-alder-biopharmaceuticals-aldr-stock-price.html.
Alder BioPharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.